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Abstract
 
The CD1 family of major histocompatibility complex (MHC)-like molecules specializes in
 
presenting lipid and glycolipid antigens to 
 
a
 
/
 
b
 
 T lymphocytes, but little is known about the
size of the CD1-restricted T cell population or the frequency of T lymphocytes specific for a
given glycolipid antigen. Here, we report the generation and use of mouse CD1d1–glycolipid
tetramers to visualize CD1d-restricted T cells. In contrast with previous BIAcore-based esti-
mates of very short half-lives for CD1d–glycolipid complexes, we found that the dissociation
rate of several different CD1d–glycolipid complexes was very slow. Fluorescent tetramers of
mouse CD1d1 complexed with 
 
a
 
-galactosylceramide (
 
a
 
GalCer), the antigen recognized by
mouse V
 
a
 
14-J
 
a
 
281/V
 
b
 
8 and human V
 
a
 
24-J
 
a
 
Q/V
 
b
 
11 natural killer T (NKT) cell T cell re-
ceptors (TCRs), allowed us for the first time to accurately describe, based on TCR specificity,
the entire population of NKT cells in vivo and to identify a previously unrecognized popula-
tion of NK1.1-negative “NKT” cells, which expressed a different pattern of integrins. In con-
trast, natural killer (NK) cells failed to bind the tetramers either empty or loaded with 
 
a
 
GalCer,
suggesting the absence of a CD1d-specific, antigen-nonspecific NK receptor. Mouse CD1d1–
 
a
 
GalCer tetramers also stained human NKT cells, indicating that they will be useful for prob-
ing a range of mouse and human conditions such as insulin-dependent diabetes mellitus, tumor
rejection, and infectious diseases where NKT cells play an important role.
Key words: T cell development • T cell receptor • V
 
a
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Introduction
 
CD1 is an MHC-like, but genetically unlinked, family of
 
b
 
2-microglobulin–associated molecules (1) that has re-
cently been shown to present lipid antigens to 
 
a
 
/
 
b
 
 T cells
(2). Human CD1b presents mycobacterial lipids such as
mycolic acid, glucose monomycolate, and derivatives of li-
 
poarabinomannan (LAM),
 
1
 
 whereas mouse and human
CD1d bind glycosylceramides (3–5) and glycosylphosphati-
dylinositol (GPI) anchors (6). X-ray crystallography studies
indicated that the groove of mouse CD1d is formed of two
large hydrophobic pockets seemingly well adapted to bind
fatty acid chains (7) and, in conjunction with functional ex-
periments (8), suggested a model whereby the hydrophobic
groove of CD1 serves to anchor the fatty acid chains of the
lipid antigens, positioning the polar head groups for recog-
nition by the TCR.
The size and diversity of the CD1-restricted T cell pop-
ulation is not fully characterized. Limited numbers of
 
CD1-restricted CD8, CD4, or CD4
 
2
 
CD8
 
2
 
 double nega-
tive (DN) T cell lines and clones expressing diverse TCRs
have been generated in vitro, but the largest populations of
CD1-restricted cells currently identified in vivo are the
CD1d-restricted, IL-4 and IFN-
 
g
 
–producing, CD4 and
DN NK T (NKT) cells (9). These NKT cells, which repre-
sent up to 30% of all T cells in the liver or bone marrow,
 
express semiinvariant V
 
a
 
14-J
 
a
 
281/V
 
b
 
8 (V
 
a
 
24-J
 
a
 
Q/V
 
b
 
11
in humans) TCRs (10), and they share several general fea-
tures with subsets of 
 
g
 
/
 
d
 
 T cells and B1 B cells, suggesting
that they belong to the innate rather than the adaptive arm
of the immune system. Their germline-encoded TCR-
 
a
 
specificity is autoreactive, leading to autoantigen-driven se-
lection and accumulation (11). Similar to mouse VH11/
V
 
k
 
9 and VH12/V
 
k
 
4 B1 B cells, which recognize the mem-
brane lipid phosphatidylcholine, mouse and human NKT
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Abbreviations used in this paper:
 
 
 
a
 
GalCer, 
 
a
 
-galactosylceramide; APC,
 
allophycocyanin; DN, CD4
 
2
 
CD8
 
2
 
 double negative; GPI, glycosylphos-
phatidylinositol; IDDM, insulin-dependent diabetes mellitus; LAM, li-
poarabinomannan; NKT cell, natural killer T cell. 
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CD1d Tetramers
 
cells recognize a glycolipid, 
 
a
 
-galactosylceramide (
 
a
 
GalCer).
Originally purified from marine sponge extracts on the ba-
sis of its antitumor property (12), 
 
a
 
GalCer appears to be
presented by CD1d to activate both mouse and human
NKT cells (3–5). Although it is unclear whether 
 
a
 
GalCer
represents the natural ligand of NKT cells or a cross-reac-
tive antigen, its recognition by virtually all mouse V
 
a
 
14-
J
 
a
 
281/V
 
b
 
8 and human V
 
a
 
24-J
 
a
 
Q/V
 
b
 
11 NKT cells sup-
ports the idea that the semiinvariant NKT cell TCRs
evolved to recognize a conserved family of glycolipids.
NKT cells regulate both mouse and human insulin-depen-
dent diabetes mellitus (IDDM) (13, 14), exert protective
functions against parasites such as 
 
Plasmodium
 
 (15) and 
 
Toxo-
plasma gondii
 
 (16), against bacteria such as 
 
Listeria
 
 (17), and
against tumors (18). These effects appear to be mediated
at least in part through their ability to explosively release
cytokines such as IL-4 and IFN-
 
g
 
 (19, 20) and to influ-
ence the Th1/Th2 outcome of adaptive T cell responses
(21, 22).
Unambiguous identification of NKT cells has proved
difficult, confusing the interpretation of several important
observations. Several mouse strains do not express the
NKRP1-A allele recognized by the anti-NK1.1 mAb,
PK136 (23). Even in positive strains such as C57BL/6,
NK1.1
 
1
 
 T cells that are neither CD1d-restricted nor V
 
a
 
14
expressers have been found in various tissues (24) and con-
versely, CD1d-autoreactive V
 
a
 
14-J
 
a
 
281–expressing hy-
bridomas have been derived from NK1.1
 
2
 
 subsets (25).
Furthermore, there exists a minor population of CD1d-
autoreactive, NK1.1
 
1
 
 T cells that expresses non-V
 
a
 
14 TCRs
(10, 25). In humans, a combination of anti-V
 
a
 
24 and anti-
V
 
b
 
11 mAbs is available (26), but it does not discriminate
between J
 
a
 
Q
 
1
 
 (canonical) or J
 
a
 
Q
 
2
 
 V
 
a
 
24/V
 
b
 
11 TCRs
and misses non–V
 
b
 
11-based canonical NKT cells.
The recent discovery that virtually all mouse and human
canonical V
 
a
 
14-J
 
a
 
281 or V
 
a
 
24-J
 
a
 
Q NKT cells recog-
nized the glycolipid antigen 
 
a
 
GalCer suggested that a simi-
lar approach to that recently developed for staining conven-
tional T cells with tetramers of MHC–peptide complexes
might be employed to identify the CD1d-restricted T cells
(27). However, unlike peptides, which can be genetically
linked to MHC molecules, lipid antigens must be bound to
CD1d after the production and purification of recombinant
CD1d molecules. Therefore, for this approach to be suc-
cessful, CD1d–glycolipid complexes must be stable, i.e.,
their dissociation rate should be sufficiently slow.
Based on the ability of soluble recombinant CD1d1 mol-
ecules loaded with 
 
a
 
GalCer and chased for various periods
of time before exposure to IL-2–producing NKT cell hy-
bridomas, we estimated that the half-life of CD1d1–
 
a
 
Gal-
Cer complexes was quite long, on the order of 1 d. This
result is in sharp contrast with a recent BIAcore-based esti-
mate of a very short half-life between 7 s and 3 min (28).
Furthermore, we found that several other lipids bound
tightly to CD1d1, suggesting that, like MHC molecules,
CD1 molecules have the ability to trap antigens for ex-
tended periods. We exploited this property to show that
mouse CD1d tetramers loaded with 
 
a
 
GalCer could be
 
used to stain both mouse and human cells expressing the
canonical 
 
a
 
GalCer-specific NKT cell TCRs. Tetramer
staining also revealed a previously unrecognized subset of
NK1.1
 
2
 
 “NKT” cells with a different pattern of expression
of 
 
a
 
4 integrins. “Empty” or 
 
a
 
GalCer-loaded CD1d tet-
ramers failed to stain NK cells, suggesting the absence of a
CD1d-specific, antigen-nonspecific NK receptor.
These results demonstrate that CD1d tetramers can be
used to probe the glycolipid-specific CD1d-restricted T
cell repertoire in vivo. Furthermore, they provide the first
accurate identification of NKT and NKT-like CD1d-
restricted T cells in vivo in mice and humans, allowing fur-
ther dissection of their important regulatory functions in
conditions such as IDDM, tumor rejection, and infectious
diseases.
 
Materials and Methods
 
Mice.
 
C57BL/6 mice were obtained from Taconic Farms.
CD1d-deficient mice were generated in our laboratory and used
after 7–12 backcrosses to C57BL/6 (29). V
 
a
 
14-J
 
a
 
281 TCR 
 
a
 
chain transgenic mice were generated in our laboratory (10) on a
C57BL/6 background and crossed to C57BL/6.TCR C
 
a
 
2
 
/
 
2
 
(The Jackson Laboratory). Mouse studies followed the Institu-
tional Animal Care and Use Guidelines.
 
Construction, Expression, and Purification of Mouse Biotinylatable
CD1d1 Molecules.
 
Recombinant soluble CD1d1 molecules
were produced in a fly expression system as reported for other
class I and class II MHC molecules (30, 31). The cDNA coding
for the mouse CD1d1 heavy chain (32) was interrupted at the
third domain–transmembrane junction by PCR and cloned in
frame between the EcoR1 and Bgl2 sites of the pRHMa3/6His
inducible fly expression vector. The biotinylation sequence no.
45 of Schatz (33) was added by opening the Bgl2 site and ligating
in the linker 5
 
9
 
-CTGGGTGGTATCTTCGAGGCTATGAA-
GATGGAGATGCGCGAT-3
 
9
 
. The 3
 
9
 
 end of the Bgl2 site was
substituted by a GGA TCT sequence, to destroy the site and to
encode G S instead of R S residues before the histidine tail. The
mutagenesis was confirmed by sequencing. SC2 
 
Drosophila melano-
gaster
 
 cells were transfected by calcium phosphate precipitation
with the modified heavy chain and mouse 
 
b
 
2-microglobulin
cDNAs and a constitutive neomycin resistance gene at a ratio of
60:60:1. After 3 wk of G-418 selection, resistant cell lines were
tested for expression after a 3-d induction with 0.7 mM CuSO
 
4
 
.
Individual clones were subsequently derived by limiting dilution
and selected for high expression. Large scale preparations were
carried out in X-press serum-free medium (BioWhittaker) and
expanded to 10–12 liters in roller bottles. Supernatants from in-
duced cells were harvested by centrifugation and concentrated by
tangential flow down to 400 ml. CD1d1 molecules were affinity
purified by Ni-NTA-agarose chromatography from the concen-
trate. Further purification was carried out by anion exchange
chromatography on a MonoQ 10/10 column (Amersham Phar-
macia Biotech), and purity was checked by SDS-PAGE.
Biotinylation was done according to the manufacturer’s in-
structions for 16–24 h at room temperature (Avidity). Biotinyla-
tion was then quantitated by using HABA colorimetric reagent
(Pierce Chemical Co.) and immunoprecipitation with streptavi-
din-agarose beads (Pierce Chemical Co.). Efficiency was always
 
.
 
90%. Protein concentration was measured by microBCA
(Pierce Chemical Co.). 
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Loading of CD1d1 with 
 
a
 
GalCer and Generation of Fluorescent
Tetramers of CD1d1–
 
a
 
GalCer for Flow Cytometry.
 
Soluble biotin-
ylated recombinant CD1d1 molecules were incubated for 18 h
with various concentrations of 
 
a
 
GalCer diluted in PBS from a
220 
 
m
 
M stock solution in 0.5% Tween 20, and free 
 
a
 
GalCer was
removed by centrifugation dialysis in a Microcon YM-30 tube
(Millipore). Tetramers were generated by mixing 
 
a
 
GalCer-
loaded monomers with fluorochrome-labeled streptavidin (strepta-
vidin-PE or streptavidin-Cychrome, 5:1 ratio; BD PharMingen)
without further separation by gel filtration. Staining was per-
formed by incubating cells on ice for 3 h with tetramers at a con-
centration equivalent to 20 
 
mg/ml of CD1d1. For staining with
monomers, fluorochrome-conjugated streptavidin was added af-
ter the cells had been previously incubated for 3 h with 20 mg/ml
of biotinylated aGalCer-loaded CD1d1.
Stimulation of Mouse T Cell Hybridomas by Preformed CD1d1/
aGalCer Complexes. The CD1d-restricted DN32.D3 and
431.G5 NKT cell hybridomas expressing canonical Va14-
Ja281/Vb8 TCRs, and the CD1d-restricted hybridoma 431.A11
expressing Va3.2-Ja8/Vb8.2, were generated in our laboratory
and described previously (10, 34). RF33.70, a Kb/OVA-specific
hybridoma was a gift of K. Rock (University of Massachusetts,
Worcester, MA). For T cell hybridoma stimulation, purified re-
combinant mouse CD1d1 molecules were coated for 12–18 h at
2.5 mg/ml in PBS on 96-well plates. After washing with PBS,
CD1d1-coated wells were incubated for 2 h with aGalCer (a gift
from Dr. Y. Koezuka, Pharmaceutical Research Laboratory, Ki-
rin Brewery Co., Ltd., Takasaki, Japan) diluted into PBS from a
220 mM stock solution made in 0.5% Tween 20 or from a 100
mM stock solution made in 50% DMSO. After extensive washes
with PBS, 50,000 hybridoma cells were added in a 1:1 mixture of
EHAA and RPMI (Biofluids) supplemented with 10% FCS, 5 3
1025 M 2-ME, penicillin-streptomycin-gentamicin, glutamine.
Supernatants were harvested after 18–24 h to measure IL-2 re-
lease using CTLL cells as described.
Lipid Binding to CD1d1. To test whether other lipids bound
CD1d1, we used a modification of the plate-bound CD1d1 hy-
bridoma stimulation assay. Here, CD1d1 was preincubated for 6 h
with LAM purified from Mycobacterium tuberculosis (a gift from J.
Belisles, Colorado State University, Fort Collins, CO) or gangli-
oside GM1 (G-7641; Sigma-Aldrich) before washing and incu-
bating for 2 h with aGalCer as described above. After washing,
the aGalCer-responsive DN32D3 hybridoma cells were added to
the microwells.
Human PBL Stimulation with aGalCer. PBLs were centri-
fuged through Ficoll-Paque (Amersham Pharmacia Biotech) and
stimulated with 0.1 mM aGalCer at 4 3 105 cells per microwell
in RPMI with 10% FCS supplemented with glutamine and anti-
biotics. After 7 d in culture, blasts cells were recovered by centrif-
ugation through Ficoll and processed for flow cytometry staining.
mAbs and Flow Cytometry. FITC-conjugated anti–panTCR-b,
Vb8.1/8.2, Vb7, Vb2, Vb6, Ly6C, CD44, CD49d, CD69,
CD122, CD4, and CD8, CD5-Cychrome, CD5-allophycocya-
nin (APC), NK1.1-PE, and streptavidin-Cychrome were ob-
tained from BD PharMingen. FITC- and PE-conjugated anti–
human Va24 and Vb11 were obtained from Immunotech.
FITC-conjugated Y3P anti–I-Ab was prepared in our laboratory.
Samples were analyzed using a FACS Vantage™ (Becton Dickin-
son) equipped with argon and dye lasers or a four-color FAC-
Sort™ equipped with argon and 635-nm diode lasers (Becton
Dickinson) and CELLQuest™ software.
Generation of A-LAK Cells. Splenic A-LAK cells were gener-
ated after stimulation of nylon wool–passed C57BL/6 splenic
cells with 1,000 U IL-2/ml for 5–7 d, as described by Chang et
al. (35). Both day 3 adherent and day 3 nonadherent cells that
subsequently readhered to plastic were examined.
Results
Long Life Span of CD1d1–Glycolipid Complexes. Stable
binding of glycolipid antigens to CD1d1 is a prerequisite
for tetramer staining of glycolipid-specific T cells. Fig. 1 A
shows that plate-bound recombinant CD1d1 was able to
present aGalCer to NKT cells (in line with a recent report
[28]), and that the half-life of CD1d1–aGalCer complexes
Figure 1. Long life span of CD1d1–glycolipid complexes. (A) Plate-bound CD1d1 (2.5 mg/ml) was loaded with 0.1 or 0.3 mM aGalCer for 2 h,
washed, and chased for different periods of time before adding the Va14-Ja281 NKT cell hybridoma DN32D3 and measuring IL-2 release in the super-
natant (mean 6 SD). (B) Plate-bound CD1d1 was first incubated with 30 mg/ml of LAM or GM1 for 6 h, washed, and chased for different periods of
time. 0.1 mM aGalCer was added for 2 h and washed before incubation with DN32D3. (C) Microwells were coated overnight with 2.5 mg/ml CD1d1
or BSA or 0.1mM aGalCer, washed, then pulsed for 2 h with 0.1 mM aGalCer as indicated, and washed again before adding the CD1d-restricted Va14
hybridomas DN32D3 or a control CD1d-restricted non-Va14 hybridoma, 431.A11 (Va3.2-Ja8/Vb8), and measuring IL-2 release (mean 6 SD).
431A11 and DN32D3 produced similar amounts of IL-2 when stimulated with CD1d1-expressing thymocytes.1898 CD1d Tetramers
was remarkably long. We performed chase experiments by
washing the wells after loading plate-bound CD1d1 with
aGalCer. As a readout assay, we used IL-2 production
from the aGalCer-responsive T cell hybridoma DN32D3,
which expresses the canonical Va14-Ja281/Vb8 TCR,
and found that stimulation after loading with limiting con-
centrations of aGalCer was virtually unchanged 12 h after
washing off aGalCer. Given that prolonged engagement of
the TCR is needed for optimal IL-2 production by T cells
in the readout assay, a half-life well in excess of 12 h can be
estimated, a result that is more than two orders of magni-
tude higher than the previous estimates of 7 s to 3 min de-
rived from the BIAcore studies (28). Experiments using
CD1d1-transfected cells pulsed with aGalCer also sup-
ported a long life span of the CD1d1–aGalCer complexes,
as these cells maintained their stimulatory properties for
several days after chase (not shown). However, it is difficult
to rule out the possibility of lipid uptake and gradual release
from some cellular storage compartment in this system.
The remarkable antigen-trapping property of CD1d1
was not limited to aGalCer. Soluble CD1d1 molecules
preincubated with various lipids including a ceramide- and
a phosphatidylinositol-based glycolipid (GM1 and LAM,
respectively) were refractory to aGalCer binding as judged
by inhibition of NKT cell stimulation. Loading of aGalCer
was inhibited for extended periods of time (.6 h) after
these lipids had been washed off the wells (Fig. 1 B). These
competition experiments suggest that, in addition to aGal-
Cer, other ceramide- or phosphatidyl-containing glycolip-
ids also bind tightly, with a slow off rate, to CD1d1.
Fig. 1 C shows that CD1d1 alone did not stimulate
DN32D3, suggesting that the natural ligand recognized by
this CD1d1-autoreactive hybridoma was not present in the
preparation made in Drosophila cells. CD1d1–aGalCer
complexes did not stimulate 431.A11, a control CD1d1-
restricted Va3.2-Ja8/Vb8 hybridoma also derived from
thymic NKT cells. Presentation of aGalCer required
CD1d1, as uncoated wells or wells coated with BSA were
not stimulatory. In addition, several control lipids failed to
stimulate NKT cells but nevertheless inhibited presentation
of aGalCer to NKT cells (Fig. 1 B, and data not shown),
suggesting that they competed with aGalCer for binding to
CD1d1.
Staining with Monomers and Tetramers of CD1d1–aGalCer.
We exploited this long half-life of biotinylated CD1d1–
aGalCer complexes to stain NKT cells expressing the ca-
nonical Va14-Ja281 TCR a chain. Fig. 2 A shows that
CD1d1 monomers that had been loaded overnight with
20 mM  aGalCer significantly, albeit weakly, stained a
Va14-Ja281 NKT cell hybridoma. The aGalCer-loaded
monomers retained their ability to stain NKT cells for ex-
tended periods of time after dialysis (not shown), confirm-
ing the very slow rate of dissociation previously measured
with the T cell hybridoma assay. As expected, the same
concentration of CD1d1–aGalCer complexes in tetrameric
form showed much higher level of binding to NKT cells
(Fig. 2 B). No staining was observed with empty tetramers,
whereas examination of the binding curve of tetramers
loaded over a range of concentration of aGalCer (mea-
sured via the fluorescence intensity of the T cell hybrid-
oma, Fig. 2 C) revealed evident cooperative effects at
ranges between 3 and 10 mM of aGalCer. The Hill coeffi-
cient of 4.5 measured in Fig. 2 C is in line with the need
for occupancy of all four CD1d1 molecules of the tet-
ramer by aGalCer to confer high avidity to the Va14-
Ja281 TCR.
The specificity of CD1d1–aGalCer for canonical CD1d-
restricted Va14-Ja281 TCRs was investigated. Fig. 3 showed
that the aGalCer-loaded but not the unloaded tetramers
Figure 2. Binding of CD1d1–
aGalCer complexes to a Va14-
Ja281/Vb8 NKT cell hybrid-
oma. (A) Biotinylated monomers,
revealed with streptavidin-PE.
(B) Streptavidin-PE tetramers.
(C) Binding curve of CD1d1
tetramers loaded at different
concentrations of aGalCer;
binding was measured by flow
cytometry analysis (mean fluo-
rescence intensity, MFI). Hill
Coeff., Hill coefficient (see Ma-
terials and Methods).
Figure 3. CD1d1–aGalCer tetramers specifically stained Va14-Ja281
NKT cell hybridomas. “Empty” or aGalCer-loaded tetramers and anti–
TCR-b mAb were used to stain two canonical Va14-expressing, aGalCer-
responsive hybridomas (DN32D3 and 431G5), one CD1d1-restricted
aGalCer-unresponsive Va3.2 hybridoma (431A11), and one Kb-restricted
Va2 hybridoma (RF33.70).1899 Benlagha et al.
stained two different Va14-Ja281 hybridomas (DN32D3
and 431G5, expressing different Vb chains) with a similar
profile as an anti–TCR-b antibody. In contrast, the tet-
ramers did not stain a CD1d1-restricted Va3.2-expressing
hybridoma or a Kb-restricted Va2-expressing hybridoma.
Specificity for the TCRs was further demonstrated by
blocking with anti-TCR antibodies (see Fig. 7) and by
TCR gene transfer (see experiment with Va14-Ja281
transgenic cells below).
In Vivo Staining of Fresh NKT Cells. Fig. 4 A shows that
CD1d1–aGalCer tetramers stained 1% of the MHC class
II–negative population of splenocytes in C57BL/6 mice.
These CD1d1–aGalCer tetramer-positive splenocytes cor-
responded to the CD1d-restricted cells expressing the
Va14-Ja281 canonical TCR a chain by the following cri-
teria. They expressed the T cell marker CD5, they were
absent in CD1d-deficient mice, and their frequency in-
creased up to 30-fold in Va14-Ja281 TCR a chain trans-
genic mice. In normal mice, most tetramer-positive spleen
or liver cells exhibited a CD41 phenotype and the remain-
der were DN, with very few CD8 cells. In the Va14-
Ja281 transgenic mice, the ratios were reversed: 73% cells
were of the DN phenotype, with only 21% CD41 and 5%
CD81 (Fig. 4 B).
The TCR Vb repertoire of these cells was next analyzed
by flow cytometry. Fig. 5 A shows that, as reported for
NKT cells, CD1d1–aGalCer tetramer-positive splenocytes
from normal mice were considerably enriched in Vb8-,
Vb7-, and Vb2-expressing cells compared with the main-
stream T cells that are MHC, rather than CD1d restricted.
Moreover, tetramer-positive cells expressed intermediate
levels of surface TCR (Fig. 5 A, TCR-b histograms).
In the Va14-Ja281 transgenic mice, a subset of CD51
cells did not bind the CD1d1–aGalCer tetramer (Fig. 4 A,
right). As a proportion of these cells was likely composed of
T cells expressing endogenous rather than transgenic TCR
a chains, we examined Va14-Ja281 TCR a chain trans-
genic cells from mice bred to a TCR Ca null background.
Fig. 5 B shows that z40% of CD51 cells that solely ex-
pressed the Va14-Ja281 TCR a chain nevertheless re-
mained unstained by the tetramers. Further, in contrast
with the tetramer-positive subset, these cells were uni-
formly NK1.12 (not shown) and did not exhibit an in-
creased frequency of Vb8, Vb7, or Vb2 usage. In fact, they
were almost completely depleted of these Vbs while ex-
pressing compensatory increases in other Vbs such as Vb6
(Fig. 5 B). These results demonstrate that virtually all Vb8,
Figure 4. CD1d1–aGalCer tetramers stained CD1d1-restricted Va14-
Ja281 NKT cells in vivo. (A) Spleen cells from wild-type, CD1d-deficient,
or Va14-Ja281 TCR a chain transgenic mice in a C57BL/6 background
were stained with CD1d1–aGalCer tetramers-PE, CD5-Cychrome, and
anti–I-Ab–FITC. Dot plots were gated on MHC class II2 splenocytes. (B)
Splenocytes from normal mice and Va14-Ja281 TCR a chain transgen-
ics were stained with tetramer-Cychrome, CD5-APC, and anti-CD4 or
CD8-FITC. Histograms display the frequency of CD41 and/or CD81
cells among gated CD51 tetramer1 splenocytes.
Figure 5. CD1d1–aGalCer tetramer1 cells exhibit
intermediate levels of surface TCR and a bias in Vb
usage. Splenocytes from normal mice (top) and Va14-
Ja281 TCR a chain transgenics in a C57BL/6.TCR
Ca2/2 background (bottom) were stained with tet-
ramer-Cychrome, CD5-APC, and anti-Vb–FITC.
Histograms display the frequency of Vb1 cells among
CD51  tetramer1 and CD51 tetramer2 splenocytes
gated as indicated.1900 CD1d Tetramers
Vb7, or Vb2 TCR b chains combined with Va14-Ja281
have specificity for aGalCer, suggesting that the TCR
CDR3b region is permissive for but does not specifically
contribute to recognition of CD1d1–aGalCer complexes.
Altogether, these striking results parallel previous obser-
vations on TCR-b and CD4/8 expression by natural as
well as transgenic Va14-Ja281 NKT cells, indicating that
aGalCer is a very close mimic of the natural ligand of
Va14-Ja281 NKT cells and underscoring the value of
CD1d1–aGalCer tetramers as probes for identifying all
CD1d1-dependent Va14-Ja2811 cells.
A Distinct Population of NK1.12 Va14-Ja2811 NKT-like
Cells. A subset of CD1d1–aGalCer tetramer-positive cells
appeared to be NK1.12, in normal as well as in Va14-
Ja281 transgenic mice. The frequency of these cells varied
between 15 and 50% of tetramer-positive cells in different
tissues and in individual mice. We studied their phenotype
by multiparameter flow cytometry. Like NK1.11 T cells,
they exhibited other features of NKT cells, such as the bi-
ased expression of Vb8 (Fig. 6), Vb7, and Vb2, and a
CD44hiCD691CD1221Ly6Chi phenotype (not shown), but
they differed strikingly from NK1.11 cells by their upregu-
lated expression of CD49d (a4 integrins) (Fig. 6). There-
fore, these data identify a novel subset of CD1d-restricted
Va14-Ja2811 cells that escaped previous recognition based
on NK1.1 staining and may express a number of distinct
properties, in particular with respect to migration patterns.
Human Va24-JaQ/Vb11 NKT Cells Bind to Mouse
CD1d1–aGalCer Tetramers. The well-known conserva-
tion of mouse and human CD1d and NKT TCRs was re-
cently extended by reports that aGalCer could be recog-
nized in both species, irrespective of the mouse or human
CD1d1 molecule used as the antigen-presenting molecule
(4, 5). These observations suggested that mouse CD1d1–
aGalCer tetramers might also be a useful tool to identify
human Va24-JaQ NKT cells. Fig. 7 shows that 2% of hu-
man PBLs expressed Va24-JaQ/Vb11 after expansion
with one round of stimulation with human CD1d-express-
ing cells and aGalCer. These cells were brightly stained by
mouse CD1d1–aGalCer tetramers, and this staining was
specific for the Va24/Vb11 cells as shown by costaining
with anti-Vb11. Furthermore, preincubation of the cells
with anti-Va24 inhibited tetramer staining of Vb111 cells,
formally demonstrating that the CD1d1–aGalCer tetra-
mers bind the TCRs (Fig. 7, bottom). A similar inhibition
of tetramer staining could be observed in the mouse system
with some but not all anti-Vb antibodies (not shown),
probably depending on their TCR binding site.
Neither Empty Nor aGalCer-loaded CD1d1 Tetramers Stained
NK Cells. The NK receptors of NK cells can be stained
with mono- or multimers of their MHC ligands, sometimes
in a peptide-independent manner (36). As CD1d1 was re-
ported to inhibit killing of RMA/s cells by spleen-derived
NK cells (35), we examined the NK1.11 splenic popula-
tion for staining with CD1d1–aGalCer tetramers. Fig. 8 A
shows that only NK1.11 T cells (TCR-b1) were stained
by the CD1d1–aGalCer tetramers, whereas fresh NK cells
(TCR-b2) exhibited near background staining level (,1%).
Unloaded “empty” tetramers also failed to stain fresh NK
cells (not shown). Fig. 8 B shows that A-LAK cells gener-
ated from IL-2–activated splenic cultures also failed to bind
the CD1d1 tetramers.
Thus, these results suggest the absence of antigen-inde-
pendent CD1d-specific NK receptor. It remains possible,
as shown for HLA-E/Qa1–specific CD94/NKG2 recep-
tors (37, 38), that NK receptor binding to CD1d1 requires
the presence of a particular antigen, or is influenced by the
glycosylation of CD1d1, which is altered in molecules pro-
duced in insect cells.
Interestingly, Fig. 8 A also showed that a substantial frac-
tion (z20–40%) of splenic NK1.11 TCR-b1 cells did not
bind the CD1d1–aGalCer tetramers. These cells exhibited
a predominantly DN phenotype with no bias in Vb8 ex-
pression (not shown), and likely correspond to the CD1d-
independent NKT cells described by others (24).
Figure 6. A subset of CD1d1–aGalCer tetramer1 cells
are NK1.12 and express upregulated levels of CD49d.
Liver lymphocytes from normal C57BL/6 mice were
stained with tetramer-Cychrome, NK1.1-PE, and anti-
Vb–FITC or CD49d-FITC. Note that most tetramer1
NK1.11 cells were CD49d2 whereas tetramer1 NK1.12
cells were CD49d1. Both subsets exhibited the same bias
in Vb8 (middle) and Vb7 and Vb2 (not shown). Similar
results were found for splenocytes and in Va14-Ja281
TCR a chain transgenic mice.
Figure 7. Mouse CD1d1–aGalCer tetramers stain human Va24/Vb11
NKT cells. Human PBLs were stimulated with 0.1 mM aGalCer in vitro
and stained after 7 d in culture. In this experiment, CD1d1-mediated
aGalCer presentation to NKT cells is provided by the PBLs themselves.
After centrifugation through Ficoll, the cells were preincubated with anti-
TCR antibodies for 1 h before adding tetramer-PE. Note that anti-Va24
completely blocks tetramer binding.1901 Benlagha et al.
Discussion
This report demonstrates several important features rele-
vant to CD1d-mediated antigen presentation and recogni-
tion by T cells. First, using soluble recombinant mouse
CD1d1 to present lipid antigens to CD1d-restricted T cell
hybridomas, we found that CD1d1 could tightly bind (i.e.,
with a slow dissociation rate) several lipids, including aGal-
Cer, the marine sponge antigen recognized by mouse and
human NKT cells. These results stand in marked contrast
to those recently reported using plasmon resonance to
measure the on and off rates of lipid binding to CD1d1. A
very rapid off rate with a half-life of CD1d–aGalCer com-
plexes on the order of 7 s to 3 min was measured in these
experiments (28), thus underestimating by two to three or-
ders of magnitude the actual life span of these complexes as
read out by T cell hybridomas. Although it should be
stressed that our studies are based on an indirect functional
assay, the findings do indicate that CD1d–glycolipid com-
plexes are stable and the results are more likely to be rele-
vant to normal physiological situations than the markedly
different results reported in the BIAcore studies. The dis-
crepancy may be related to several technical issues associ-
ated with BIAcore technology and/or the use of a biotiny-
lated form of aGalCer with potentially altered binding to
CD1d1.
The remarkable antigen-trapping property of CD1d1
that we found is similar to that of MHC class I and II and
consistent with the antigen-presenting function of CD1d1
in that it would enable the antigen-presenting cells to re-
tain, for an extended period of time, the lipid antigens cap-
tured in infected tissues. We exploited it to generate
monomers and tetramers of biotinylated CD1d1 stably
complexed with aGalCer, and found that they specifically
bound to NKT cells as revealed by multiparameter flow
cytometry. The staining intensity of NKT cells by the pre-
formed CD1d1–aGalCer complexes did not vary even af-
ter free aGalCer was removed by dialysis and complexes
were chased for up to 6–12 h (not shown), further demon-
strating the stability of aGalCer binding to CD1d1. As ex-
pected given the avidity gain associated with the tetrameric
form of CD1d1, CD1d1–aGalCer tetramers stained NKT
cells with z50-fold greater fluorescence intensity than the
monomers.
CD1d1–aGalCer tetramers exactly identified CD1d-
restricted NKT cells expressing the canonical Va14-Ja281
TCR a chain, including their intermediate level of surface
TCR, Vb bias and CD4/CD8 pattern of expression and, as
expected, they also labeled the human NKT cell subset. In
addition, they revealed a previously unrecognized NK1.12
“NKT” cell that closely resembled the NKT cell with re-
gards to the expression of canonical TCRs with biased Vbs
and of a large panel of phenotypic markers. One notable
exception consisted in the upregulated levels of a4 inte-
grins, which are not expressed on NK1.11 NKT cells. The
significance of this novel subset is unclear at present. It
could reflect a different functional state of the mature
Va14-Ja281 T cell endowed with different functional or
migratory properties. In that regard, experiments con-
ducted in vitro showed that NK1.1 expression is down-
modulated after TCR activation (39; and data not shown),
strongly suggesting that the NK1.12 NKT cells are acti-
vated, migrating cells. An alternative, but not exclusive
possibility, is that NK1.12 NKT cells represent a different
developmental stage or product of Va14-Ja281 T cell pre-
cursors. It will be interesting to further analyze potential
functional differences between NK1.11 and NK1.12 sub-
sets since they could well be relevant in several conditions,
such as IDDM, which is associated with generic defects in
NKT cell number or function.
The remarkable identity between the populations de-
fined by CD1d1–aGalCer tetramers and the NKT cell
population suggests a high degree of similarity between
aGalCer and the putative natural ligand(s) recognized by
NKT cells, which extends to the human system. These data
conflict somewhat with the recent suggestion (40) that GPI
anchors, the prominent endogenous ligands associated with
CD1d1, might be the actual antigens recognized by Va14-
Ja281 NKT cells, as GPI and aGalCer exhibit significant
structural differences in both their fatty acid and carbohy-
drate components. Our own recent experiments do not
lend support to this hypothesis, because we found that
CD1d1-expressing GPI-deficient cell lines were as effi-
ciently recognized by CD1d-autoreactive Va14-Ja281
NKT cells as their GPI-sufficient counterparts (Bendelac,
A., unpublished data). Thus, although the nature of the an-
tigen recognized by Va14-Ja281 NKT cells remains elu-
sive and controversial, aGalCer certainly represents a near
perfect mimic in terms of TCR recognition and thus func-
tion.
Our results demonstrate that stable CD1–glycolipid
complexes can be generated and used to probe in vivo the
glycolipid-specific CD1d-restricted T cell repertoire. The
CD1d1–aGalCer tetramers will be useful in dissecting
many aspects of the biology of mouse and human NKT
cells, including their peculiar development and their im-
portant functions in IDDM, tumor rejection, and infec-
tious diseases.
Figure 8. CD1d1–aGalCer tetramers do not stain NK cells. Fresh sple-
nocytes (A) or spleen-derived A-LAK cells (B) were stained with CD5-
APC, NK1.1-PE, tetramer-Cychrome, and TCR-b–FITC. Less than 1%
of NK cells (a/b sTCR2NK1.11) were tetramer1.1902 CD1d Tetramers
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